Shionogi & Co., Ltd. (SGIOY) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - Specialty & Generic industria. La empresa tiene su sede en Osaka, Japan. El CEO actual es Isao Teshirogi.
SGIOY tiene fecha de IPO 2015-12-01, 4,955 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $17.7B.
Shionogi & Co., Ltd. is a Japan-based pharmaceutical company founded in 1878 and headquartered in Osaka, engaged in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices. The company's marketed products include Fetroja for multidrug-resistant gram-negative bacterial infections, Xofluza for influenza, and Tivicay for HIV treatment, complemented by a robust pipeline of investigational drugs spanning infectious diseases, oncology, neurology, pain management, and other therapeutic areas. Shionogi maintains strategic collaboration agreements with leading Japanese research institutions including Nagasaki University, the National Institute of Infectious Diseases, and Kitasato University to advance antimalarial drug development. The company has also developed diagnostic solutions, including COVID-19 antibody test kits, supporting its diversified healthcare portfolio.
